The stock has been above $5 most of the time.
It is only that Lenbasaum, their leading drug, has failed in one of the clinical studies, that is why the stock plummeted in Sep 2020.
Nonetheless, they have couple others ongoing studies and they may have a chance to recover to pre-covid levels.
Before the September news their ratings were Buy and Outperform at $12, $22 and even $40 levels.
Mind the fundamentals and news.
It is only that Lenbasaum, their leading drug, has failed in one of the clinical studies, that is why the stock plummeted in Sep 2020.
Nonetheless, they have couple others ongoing studies and they may have a chance to recover to pre-covid levels.
Before the September news their ratings were Buy and Outperform at $12, $22 and even $40 levels.
Mind the fundamentals and news.
Nota
Idea workedAnd it may still have some potential
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.